These 3 Dividend Stocks Paid Out Over 90% of Free Cash Flow, but 1 Has Raised Its Dividend 54 Years in a Row

PepsiCo (PEP) paid out 101% of its free cash flow in the first 36 weeks of its fiscal year, maintaining a 54-year streak of dividend increases. AbbVie (ABBV) paid 92% of its free cash flow in dividends, with growth driven by Skyrizi and Rinvoq. Western Midstream (WES) paid 142% of its free cash flow in distributions, with growth spending causing the shortfall.

Original reporting
Published Oct 22, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 11:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
These 3 Dividend Stocks Paid Out Over 90% of Free Cash Flow, but 1 Has Raised Its Dividend 54 Years in a Row — source image
Decision brief

The 30-second read

$PEPBearishLow
01

Why it matters

Investors may reassess dividend safety, leading to modest price adjustments.

02

Market read

Dividend sustainability concerns could prompt short‑term price pressure in the three stocks.

03

What to watch

Potential for cost reductions, asset sales, or refinancing to improve cash coverage.

Relevance 4/10Novelty 2/10Timing: today

Background

The article reviews three dividend‑paying companies whose recent payouts exceed free cash flow, assessing sustainability risks.

Company-level read

Ticker impact

$PEPBearishMedium confidence
Context

PepsiCo's dividend payout covered 101% of its free cash flow for the 36‑week period, raising concerns about cash sustainability.

Expected impact

likely pressure as investors price in dividend‑coverage risk

Evidence & confidence

High payout ratio combined with lowered guidance suggests cash strain, which could prompt a share price decline.

$ABBVNeutralMedium confidence
Context

AbbVie paid 92% of its free cash flow as dividend while its debt rises from the Apogee Therapeutics acquisition.

Expected impact

moderate pressure from leverage but support from earnings growth

Evidence & confidence

Robust drug revenue offsets debt load, keeping the stock relatively balanced.

$WESBearishMedium confidence
Context

Western Midstream distributed 142% of its free cash flow, indicating a cash gap that may require debt financing.

Expected impact

likely pressure as investors worry about sustainability of high yield

Evidence & confidence

Distribution exceeding cash flow suggests future cuts or financing strain, which could hurt the price.

Market effects

Highlights dividend‑coverage risk in consumer staples, pharma, and midstream sectors.

U.S. equities may see modest pressure in dividend‑focused funds.

Limited; primarily U.S. listed dividend investors.

Counterpoint

High yields may still attract income investors despite cash gaps.

Key entities

  • PepsiCo

    Consumer beverages and snacks maker

  • AbbVie

    Pharmaceutical firm

  • Western Midstream Partners

    Energy infrastructure partnership

Related articles

$WESMed

Stifel cuts Western Midstream stock price target on margin weakness

Stifel reduced its price target for Western Midstream Partners (WES) to $50 from $55, citing weaker margins and lower volumes. The stock is near its 52-week low at $41, with an 8.5x 2027E EBITDA multiple. WES reported Q3 2026 earnings of $0.78 per unit, missing estimates, though revenue matched forecasts at $1.19 billion. The company noted a 12% YoY increase in adjusted EBITDA to $708 million, driven by volumes and acquisitions.

$ABBVHigh

Nxera signs $1.47bn AbbVie licensing deal

Nxera Pharma has signed a $1.47bn global licensing deal with AbbVie for NXE0033744, an IBD treatment. Nxera receives $100m upfront and potential milestone payments. The deal is subject to antitrust clearances. NXE0033744 targets unmet needs in IBD with a novel mechanism. AbbVie gains exclusive rights to develop and commercialize the drug.

$PEPMed

PepsiCo to Cut About 1,000 Jobs After Weak North America Sales

PepsiCo plans to cut 1,000 jobs to improve operations in North America, where sales have been weak. The company lowered its 2026 guidance last month, citing slower-than-expected recovery. Shares closed at $141.88, down 1% YTD. According to CNBC, the company aims to streamline operations and strengthen team collaboration.

$JNJMed

J&J and Protagonist’s Icotyde improves psoriatic arthritis but AbbVie’s Skyrizi likely to reign

J&J and Protagonist's Icotyde showed improvement in psoriatic arthritis in a Phase 3 trial, with 58% of patients achieving a 20% improvement in disease activity. However, analysts at BMO Capital Markets noted that the results fell short of AbbVie's Skyrizi, which has a 23% placebo-adjusted improvement. Skyrizi's stronger efficacy and dosing schedule may give it an edge, but Icotyde's oral administration could appeal to patients who prefer to avoid injections.